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ABSTRACT
Novel designed metal ligand complexes as prodrugs are useful in the effort to find more
effective and selective anti-cancer treatments. Carbon monoxide, CO, is known to induce
mitochondrial collapse in cancer cells. Herein is described the synthesis of seven novel
bipyridine flavonolate palladium(II) and platinum(II) complexes with the property of
releasing carbon monoxide, and their characterization with FTIR, UV-Vis, fluorescence,
NMR, and ESI mass spectra. Their ability to release carbon monoxide was investigated
through oxygenation reaction under various conditions of temperature and light irradiation.
The nitroxygenation reaction of the palladium complexes was also studied with nitrosyl
hydride, HNO, generated in situ from Angeli’s salt. Deoxymyoglobin was used to trap CO
released from the complexes, and the reaction was monitored spectroscopically. The
spectra showed that oxygenation reaction did not produce CO in the palladium complexes
but did in the platinum complexes with irradiation, whereas nitroxygenation reaction did
in the palladium complexes.
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CHAPTER 1 - INTRODUCTION
Cancer is a disease characterized by frequent cell division, lack of regulated cell death,
angiogenesis and increased glycolysis.1 Direct medical expenses of cancer cost Americans
an estimated $80.2 billion in 2015 according to the Agency for Healthcare Research and
Quality (AHRQ).2 Current anticancer drugs face limitations such as development of drug
resistance, lack of selectivity, and low efficacy.3 The medical community needs new cancer
treatments.
Effectively fighting cancer requires a multi-faceted approach, perhaps combining
treatments like radiotherapy, hormone therapy, chemotherapy and immunotherapy. Rather
than targeting the cancer cells directly, immunotherapy attempts to activate and boost
natural anti-cancer immune responses with therapies such as cancer vaccines3 and targeting
immune system checkpoint inhibitors.4 Although immunotherapy is very promising, even
the most successful immunotherapies induce adverse side effects in 60-75% of the
patients.3–5 Immune checkpoint inhibitors can cause widespread inflammation, resulting in
diseases like diabetes, hepatitis, or tuberculosis depending on which organ becomes
inflamed.6 More research is needed to better understand the effective combinations and
durations of therapies3 and to predict which patients are likely to have a serious reaction.7
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Chemotherapy drugs can work through various means, such as inducing apoptosis
(programmed cell death), interfering with cell proliferation, inhibiting angiogenesis
(creation of new blood vessels that would encourage tumor growth), and interrupting
metastasis (the spread of cancer to other parts of the body).8 Ideally a chemotherapy drug
recognizes the target cancer cell and interacts with it in multiple ways,3,9 even in the
hypoxic (low-oxygen) environment typically found in cancer cells.10 It must have adequate
aqueous solubility but not undesired side reactions.11
A prodrug (substance that undergoes a reaction during uptake and transport inside the
body11) that releases carbon monoxide could be an effective new chemotherapy. Despite
its reputation as a noxious gas, carbon monoxide (CO) is a gaseous signaling molecule in
the body, naturally regulating inflammatory mediators. As an anti-inflammatory agent, it
gives cytoprotection to healthy cells.12,13 CO is beneficial in slowing the proliferation of
some cancers by limiting angiogenesis activated by reactive oxygen species (ROS).
Tumors characteristically overproduce ROS.14–16 CO targets the cancer cell’s mitochondria
by accelerating oxidative metabolism and inducing mitochondrial collapse.12,14 It can even
amplify the effectiveness of other chemotherapy drugs used in combination with it. 14 One
study showed that murine prostate cancer treated with low concentrations of carbon
monoxide followed by the chemotherapy agent camptothecin amplified the effect of the
drug 1000-fold.14 This drug sensitization of only cancer cells but not normal cells means
lower doses could be used, resulting in fewer adverse side effects and less chance of
developing drug resistance.
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The objectives pursued in this thesis are to synthesize novel bipyridine platinum and
palladium flavonolate complexes and to determine their photo-induced carbon monoxide
release as potential anticancer agents. The research includes characterizing these novel
complexes by FTIR spectroscopy, UV-Vis spectroscopy, fluorescence spectroscopy, ESI
high resolution mass spectrometry, 1H and 13C NMR spectroscopy and elemental analysis.
1.1 Flavonols
1.1a Structure of Flavonols
Flavonols, a subclass of flavonoids, can produce carbon monoxide molecules. About
200 flavonols have been identified in vegetables and fruits such as kale, broccoli,
cranberries, blueberries and citrus fruit.17,18 As seen in Figure 1, flavonols are made of two
benzene rings connected by a pyrone ring, an unsaturated O-heterocyclic ring with a ketone
functional group.17,19,20

Figure 1. Basic structure of a 3-hydroxyflavonol.

Flavonols are amphipathic in that the phenolic hydroxyl substituents are hydrophilic, and
the benzene rings are hydrophobic. This amphipathic nature can be advantageous to
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increase aqueous solubility and promote interaction between the flavonol as a therapeutic
agent and its biological target.21,22
1.1b Function of Flavonols
Free flavonols have anti-inflammatory, antiviral, antifungal, antibacterial, anti-allergy,
anti-diabetic, antiatherosclerotic, antithrombotic, hypolipidemic, anti-mutagenic, and
anticancer properties.3,15,17,21–23 Their healthful benefits are tied to their ability to act as free
radical scavengers.24 3-Hydroxyflavones (which have a hydroxyl group at C-3 of ring C)
have particularly shown promise as anticancer agents.3,23,25–27 The most widely studied22
flavonol, quercetin, found in tea, apple, and onion,28 exemplifies flavonols’
antiproliferative properties toward meningioma cells and colon cancer cells at 10 μM
concentrations.26 One study reports a 292-fold increase in potency against in vitro prostate
cancer when the 3-hydroxy group on the C-ring was replaced by a dibutylamino group
through a 3- to 5-carbon linker and the B ring included a catechol group. (Figure 2A).27

Figure 2. Structure of (A) a synthetic 3-O-aminoalkyl-3’,4’-O-dimethoxyflavonol,
(B) myricetin (C) TMFol,
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Naturally-occurring myricetin, a 3’,4’,5’-hydroxyflavonol, (Figure 2B) inhibits prostate
cancer cell growth with IC50 ≤ 15 μM.1,28 Additional hydroxy groups on the phenolic ring
of the flavonol can increase the complex’s antiproliferative ability due to the hydroxylated
aromatic structure.17 However, the hydroxy groups can also promote pro-oxidant activity
by reducing CuII to CuI or FeIII to FeII or by auto-oxidizing in alkaline media to generate
ROS like superoxide anions.22 This occurs particularly when the B ring has three or more
hydroxyl substituents.17 This paradox of being simultaneously pro-oxidant and anti-oxidant
is consistent with the observation that many anticancer agents also have carcinogenic
potential.1 Likewise, the generation of ROS can have a positive effect on cancer therapy
but a negative effect on chemoprevention.
Flavonols additionally inhibit signal transduction pathways and other growth regulatory
pathways in the cell.1,22 For example, they inhibit topoisomerase IIα, an enzyme
overexpressed in many types of cancer9,19 and whose inhibition interferes with DNA
replication.1,3,9,25,29,30 Flavonols also inhibit kinases which are involved in cell
metabolism.1,3,9,25,26,29,30 Having a catechol group at 3’- and 4’-positions on the B ring
confers maximum inhibition of kinases.26 Several flavonol analogues inhibit cell growth
and expression of androgen receptor and/or prostate specific antigen (PSA) in prostate
cancer.28
Flavonols work synergistically with other treatments.1 For example, the flavonol
isorhamnetin protects against cardiotoxicity induced by the platinum-based drug
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doxorubicin in vivo.1 A quercetin derivative inhibits multiple drug resistance in breast
cancer.1
A synthetic 3’,4’,5’-trimethoxyflavonol complex analogous to myricetin, TMFol,
(Figure 2C) inhibits growth at even lower IC50 values. This may be because its methoxy
(OMe) groups’ antioxidant activity is not reduced by hydrogen bonding between ligand
and solvent molecules as seen with myricetin’s hydroxyl ligands.17 Additionally, methoxyl
groups make the complex less polar than hydroxyl groups, so the molecule is more
permeable to biological membranes.26
1.1c CO-Release in Flavonols
In addition to their other anti-cancer properties, flavonols could treat cancer by releasing
carbon monoxide upon photo-irradiation in the presence of dioxygen.12,18,29,31–34 These
visible-light-activated carbon-monoxide-releasing molecules (photoCORMS) provide a
newer method to control the release of CO. They use visible light to trigger the release of
a small amount of carbon monoxide to a very specific target with less harm to healthy cells.
Visible light activation is preferred over UV-light activation since the latter has poorer
penetration and can possibly harm healthy tissue.13 Berreau et al. developed a prodrug
photoCORM in which the carbon monoxide molecule is released from a flavone.31 Since
the flavone photoCORMs have a high affinity for serum albumin, they are less likely to
released CO until the albumin has carried the oxidized form of a photoCORM to the cancer
cell. There it is reduced by biological thiols which are present in higher concentrations in
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cancer cells (Scheme 1).35 This mechanism means the CO is less likely to be released before
reaching the target. In addition to the anticancer benefits, the Berreau study noted antiinflammatory benefits of the photoCORM at nanomolar concentrations.31

Scheme 1. Reaction of photoCORM, serum albumin and thiols to release CO.
A 2017 study proposes a delivery system to release the carbon monoxide only after it
reaches the target cancer cell.32 It employs a “sense-of-logic carbon monoxide-releasing
molecule” (SL-photo-CORM) that requires two triggers to release CO. A flavonol reacts
with acryloyl chloride to produce an SL-photo-CORM. The first trigger is thiol sensing.
When the photoCORM senses biological thiols, the reverse reaction occurs creating an
activated flavonol molecule. The second trigger is visible light. When the activated
flavonol senses visible light in the presence of dioxygen, it releases a carbon monoxide
molecule and produces a non-fluorescing, nontoxic product. The reaction will occur even
in the reduced-oxygen environment typically found in cancer cells.
Several studies have focused on how carbon monoxide is released from the
flavonol.33,36,37 Natural enzymes like quercetin dioxygenase cleave the C ring of the
flavonol in a 1,3-endo-peroxide pathway to release CO.33,36 A DFT study36 proposes that
the CuII metal center of the enzyme binds to the flavonol, then the copper is reduced in a
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single electron transfer (SET) as dioxygen attacks the flavonol to form a flavonol radical
with a bridging peroxide structure, as shown in Figure 3. After this, the O-O bond and a CC bond cleave concertedly to release the carbon monoxide molecule.

Figure 3. One proposed mechanism of CO release.36
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1.2 Metalloflavonolato Complexes
1.2a Structure of Metalloflavonolato Complexes
Many researchers are taking advantage of the multiple coordination sites on transition
metals to design drugs with ligands that have anticancer properties,11 particularly
flavonols.22 Hydroxyflavones form stable coordination complexes with bidentate binding
at the hydroxyl and carbonyl groups of ring C.17,22 Flavonols may also bind to the metal
between the 5-hydroxy (ring A) and 4-carbonyl (ring C) groups or between 3’- and 4’hydroxy groups in ring B, although both of these chelations are significantly less favorable
thermodynamically than 3-hydroxy/4-carbonyl coordination.17,20,21 Due to its proximity to
the carbonyl group, the 3-hydroxyl proton on ring C is more acidic than the hydroxyl
protons on rings A and B. In the coordinate bond the 3-hydroxyl oxygen electrons are
delocalized which consequently increases delocalization of the π electrons.17 Thus the 3hydroxyl chelation is more stable than the other hydroxyl chelation sites. Metalflavonolates typically bind in a 1:1 metal:ligand (M:L) ratio but can bind in a 1:2 (M:L)
ratio with additional chelation involving ortho hydroxy groups on the B ring.17,22 The ideal
pH for complexation for most metals is pH 9.5 because this facilitates deprotonation of the
hydroxy groups to activate the flavonol.17
Steric effects of substituents on the flavonol are very influential on the anticancer
efficacy. Bulky flavonols cause steric hindrance to the metal-flavonol chelation.22 The
electronic effects of substituents on the flavonolate ligand have also been studied. For
example, the hydroxy groups have been substituted with electron withdrawing groups and
9

electron donating groups such as methoxyl, thionyl, and acetamide groups.19 The electronic
effects of these substituents appear to have only a minor effect on the cytotoxicity of the
complexes.
1.2b Function of Metalloflavonolato Complexes
Flavonol’s biological properties usually improve when the flavonol coordinates with a
metal. For example, the natural flavonol quercetin coordinated with zinc or manganese
exhibits greater anti-inflammatory properties than quercetin alone.22 Lanthanide-quercetin
complexes exhibit greater antitumor properties than free quercetin.22 The enhanced anticancer properties come from the metal binding to the cancer cell’s DNA to induce
apoptosis,10,29,30,38 combined with the anti-cancer activity of the flavonol. Also, flavonols’
solubility is improved four-fold19 or ten-fold39 when coordinated to a metal complex rather
than in unbound form. Bioavailability increases as solubility increases. Coordination also
decreases the possibility of the flavonol being metabolized to an inactive form.1,27 The
superior anticancer properties of flavonolate complexes compared to free flavonols are also
due to a reduction in the metal’s redox potential so it is less likely to form radicals.22 In
addition to this aspect of flavonolate complexes acting as antioxidants, flavonols also
directly neutralize reactive oxygen species and inhibit enzymes that catalyze processes
which generate ROS.17
Another explanation for chelated flavonols’ stronger anticancer activity compared to
free flavonols is that coordination complexes such as ruthenium-(3-hydroxyflavone)
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generally are more lipophilic than the free flavonols. This permits higher accumulation in
the cancer cell. Nevertheless, there is not a clear relationship between lipophilicity and
cytotoxicity. For example, 3’,5’-dimethoxyflavone is more cytotoxic than 3’,4’dimethoxyflavone, but the more lipophilic 3’,4’,5’-trimethoxyflavone is less cytotoxic.19
The position of substitutions on the phenyl ring seems to be more influential on cytotoxicity
than lipophilicity, perhaps due to varying amounts of twisting the ring out of plane and
therefore changing interaction with the biological target.9,19,20 Ortho substituents on the B
ring showed the lowest cytotoxicity, with a torsion angle of 60.22° seen in an o-difluorosubstituted phenyl ring.19,39 RuII(η6-p-cymene) complexes with para-chloro substituents
formed the strongest anticancer complexes.9
One significant benefit of releasing carbon monoxide from a metal-flavonolate complex
is controlled release of the CO. Controlled release is an important consideration when using
carbon monoxide as an anticancer agent. It is easier to control the release of CO from the
flavonolate ligand in a dioxygenase-type reaction than from the carbonyl in a dissociative
reaction from the metal.13,31 Metal carbonyl photoCORMs sometimes leak, that is,
spontaneously release CO before arriving at their target.31 The chance of premature release
of CO means higher concentrations of the photoCORM are needed to deliver a toxic dose
to the cancer cells with consequently increased risk to healthy cells. CO release from the
complexes can be controlled through choice of ancillary ligands.13 By selecting π-donor
ancillary ligands that increase the hyperconjugation of the complex, the HOMO-LUMO
energy gap between the metal’s d-orbitals and the CO’s π* molecular orbitals can be
11

reduced to the range of visible light. The putative first visible-light-activated photoCORM
was a dicarbonylbis(cysteamine)iron(II) complex (Figure 4) that released CO at 470nm
light irradiation.13

Figure 4. CORM-S1, a visible-light-activated photoCORM.

Well-chosen ancillary ligands can also improve solubility/bioavailability of the complex.
Ancillary ligands can ensure that the byproducts of CO release are non-toxic and easily
eliminated from the body.13
Carbon monoxide release in metal-flavonolate complexes can follow two different
pathways. One photooxygenation pathway involves a diradical intermediate that reacts
with triplet dioxygen (a diradical in the ground state). A second pathway involves a single
electron transfer from the O-heterocycle to dioxygen resulting in a tautomer of the diradical
and a superoxide ion.33 In either case, a bridging peroxide forms, followed by a concerted
C-C bond cleavage and O-O peroxide bond cleavage to release CO. The reaction without
an enzyme typically requires either UV light or visible light with high temperatures (70°C
- 80°C).33 The wavelength of light used in the photoinduced oxygenation gives different
products: UV light (300 nm) yields a 1,3 addition product, but visible light (400nm) yields
12

a 1,2 addition product.29,33 One study found that UV light yielded 0.7 equivalents of free
CO whereas visible light yielded only 0.4 equivalents.29
Many different flavonolate coordination complexes have been created, including ones
with ruthenium(II), iron(II), zinc(II), copper(II), lead(II), aluminum(III), tin(II),
cadmium(II), cobalt(II), osmium(II), and rhodium(II).17,19 Nevertheless, despite variations
in properties of these metal complexes, the anticancer effects are mainly due to bioactivity
of the O,O-chelating flavonolates ligands, rather than the choice of metal.25,39
Flavonols are promising ligands in a coordination complex because they work in
multiple ways to fight a diversity of cancer types such as bladder, breast, colon and thyroid
cancers.1,11 Bipyridine metal flavonolate complexes could provide a novel way for an
anticancer agent to deliver small amounts of carbon monoxide selectively to the cancer
cells. If the carbon monoxide efficiently targets the cancer cell, then a lower dose of the
drug would be possible, with fewer side effects and less chance of developing drug
resistance. The flavonolate complexes may contribute additional anticancer effects, such
as attacking cancer DNA, scavenging reactive oxygen species, and inhibiting enzymes to
stop cancer cell proliferation.
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CHAPTER 2 - MATERIALS AND METHODS
All reagents and solvents were obtained from commercial sources and were used as
received.

The

(2,2’-bipyridine)dichloropalladium(II)

(Pd(Bpy)Cl2),

(2,2’-

bipyridine)dichloroplatinum(II) (Pt(Bpy)Cl2), silver tetrafluoroborate (AgBF4), 3hydroxyflavone (Fla), 3-hydroxy-4’-methoxyflavone (Fla-OMe), Angeli’s salt, and
solvents were purchased from Sigma. The 3-hydroxy-4’-methylflavone (Fla-Me) and 3hydroxy-4’-chloroflavone (Fla-Cl) were obtained from Otave. FTIR data was collected on
a Perkin Elmer Spectrum 100 FTIR spectrometer. UV-Vis spectra were recorded at
ambient temperature using an Agilent HP8453 diode array spectrophotometer in a standard
UV-Vis quartz cuvette. Fluorescence data was collected on a Perkin Elmer FL6500
Fluorescence Spectrometer. High resolution mass spectra (HRMS) were obtained in the
Baylor University Mass Spectrometry Center on a Thermo Scientific LTQ Orbitrap
Discovery spectrometer using +ESI.40 1H,
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C, and 2D NMR spectra were obtained at

ambient temperature in CD3CN solution for the palladium complexes and in (CD3)2SO for
the platinum complexes, both on a Jeol ECS 400 MHz NMR spectrometer. J values are
given in Hz. A Rayonet Photochemical Reactor, RPR-100, equipped with RPR-5750A
lamps was used for all photochemical reactions. CO was detected using myoglobin assay
according to literature procedures.
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2.1 General procedure for preparation of 1-4
Silver tetrafluoroborate (AgBF4) (0.6 mmol) was dissolved in methanol (7 mL); (2,2’bipyridine)dichloropalladium(II) (Pd(Bpy)Cl2) (0.3 mmol) was dissolved in DMSO (1
mL), and then the solutions were stirred together at ambient temperature 0.5 h. Following
gravity filtration, solid 3-hydroxyflavone derivative (0.3 mmol) and triethylamine (0.7 mL)
were added to the filtrate. The reaction mixture was stirred for 0.25 h (2 h for the Fla-OMe)
at ambient temperature. The corresponding bipyridine palladium(II) flavonolato salt was
then recovered using vacuum filtration and recrystallized in CH3OH/CH3CN solvent;
remaining solvent was removed in a vacuum desiccator overnight.
2.2 General Procedure for Preparation of 5-7
Silver tetrafluoroborate (AgBF4) (0.4 mmol) was dissolved in methanol (4 mL); (2,2’bipyridine)dichloroplatinum(II) (PtII(Bpy)Cl2) (0.2 mmol) was dissolved in DMSO (4 mL),
and then the solutions were stirred together at ambient temperature 1 h. Following gravity
filtration, solid 3-hydroxyflavone derivative (0.2 mmol) and triethylamine (1 mL) were
added to the filtrate. The reaction mixture was stirred for 6 h at ambient temperature. The
corresponding bipyridine platinum(II) flavonolato salt was then recovered using vacuum
filtration and recrystallized in CH3OH/CH3CN solvent; remaining solvent was removed in
a vacuum desiccator overnight.
[(Pd(Bpy)(3-Hydroxy-4’-methoxyfla)][PF6] ] Complex 1. Yield: 70% (orange crystals)
UV-Vis λmax (CH3CN/nm)(ε/M-1 cm-1) (444 (25 200); 1H NMR (CD3CN, 400 MHz): δ 7.92
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(d, J = 6.5 Hz, 2H), 7.85 (m, J = 21.9 Hz, 4H), 7.65 (t, J = 18.7, 2H), 7.47 (d, J = 7.3 Hz,
2H), 7.28 (t, J = 11.4 Hz, 1 H), 7.19 (d, J = 6.5 Hz, 2 H), 7.13 (t, J = 13.9 Hz, 1 H), 6.66
(d, J = 8.1 Hz, 2 H); 13CNMR (CD3CN, 400 MHz): δ = 181.44, 161.13, 153.96, 153.65,
152.62, 151.82, 150.65, 148.54, 148.20, 140.94, 140.67, 138.01, 133.05, 129.37, 129.14,
127.34, 127.27, 125.04, 124.44, 124.03, 123.10, 123.01, 121.96, 121.73, 117.45, 115.53,
54.91 ppm. +ESI-MS m/z (100%) calc. 529.04; found: 529.04. Elemental analysis calc. for
C26H19BF4N2O4Pd: C 50.64%, H 3.11%, N 4.54%; found: C 50.51%, H 3.01%, N 4.52%.
[(Pd(Bpy)(3-Hydroxy-4’-methylfla)][PF6] ] Complex 2. Yield: 75% (light orange
crystals) UV-Vis λmax (CH3CN/nm)(ε/M-1 cm-1) 439 (22 200); 1H NMR (CD3CN, 400
MHz): δ 8.08 (d, J = 5.5 Hz, 1H), 8.03 (m. J = 5.5 Hz, 5H), 7.82 (t, J = 15.7 Hz, 2H), 7.70
(d, J = 7.1 Hz, 1H), 7.61 (t, J = 14.9 Hz, 1H), 7.43 (t, J = 12.6 Hz, 1H), 7.36 (m, J = 19.6
Hz, 2H), 7.27 (t, J = 14.1 Hz, 1H), 7.07 (d, J = 7.1 Hz, 2H); 13C NMR (CD3CN, 400 MHz):
δ = 183.3, 155.2, 154.8, 154.0, 153.1. 151.3, 149.4, 142.2, 141.9, 134.5, 129.7, 128.5,
128.1, 127.6, 126.2, 124.3, 122.8, 119.3, 118.3, 40.93 ppm. +ESI-MS m/z (100%) calc.
513.04; found: 513.04. Elemental analysis calc. for C26H19BF4N2O3Pd: C 51.99%, H
3.19%, N 4.66%; found: C 51.51%, H 3.11%, N 4.62%.
[(Pd(Bpy)(3-Hydroxyfla)][PF6] Complex 3. Yield: 80% (light orange crystals) UV-Vis
λmax (CH3CN/nm)(ε/M-1 cm-1) 434 (21 000); 1H NMR (CD3CN, 400 MHz): δ8.06 (d, J =
7.9 Hz, 2H), 8.01 (d, J = 5.5 Hz, 1H), 7.91 (m, J = 20.6 Hz, 3H), 7.72 (t, J = 10.3 Hz, 2H),
7.64 (d, J = 7.9 Hz, 1 H), 7.59 (t, J = 15.8 Hz, 1 H), 7.35 (m, J = 20.1 Hz, 3 H), 7.29 (t, J =
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15.2 Hz, 2 H), 7.22 (t, J = 13.3 Hz, 2 H); 13C NMR (CD3CN, 400 MHz): δ = 188, 154.8,
154.5, 153.0, 149.6, 149.0, 141.6, 141.0, 134.4, 131.4, 130.0, 128.8, 128.0, 127.8, 126.0,
123.4, 122.6 ppm. +ESI-MS m/z (100%) calc. 499.03; found: 499.02. Elemental analysis
calc. for C25H17BF4N2O3Pd: C 51.18%, H 2.92%, N 4.78%; found: C 51.11%, H 3.01%, N
4.72%.
[(Pd(Bpy)(3-Hydroxy-4’-chlorofla)][PF6] ] Complex 4. Yield: 84% (yellow crystals)
UV-Vis λmax (CH3CN/nm)(ε/M-1 cm-1) 428 (20 400); 1H NMR (CD3CN, 400 MHz): δ 7.92
(m, J = 28.1 Hz, 2H), 7.80 (d, J = 7.5 Hz, 2H), 7.76 (d, J = 5.0 Hz, 1H), 7.69 (t, J = 16.3
Hz, 3H), 7.45 (t, J = 15.6 Hz, 1 H), 7.40 (d, J = 8.1 Hz, 1 H), 7.30 (t, J = 11.9 Hz, 1 H),
7.21 (t, J = 12.5 Hz, 1 H), 7.11 (d, J = 8.1 Hz., 1 H), 7.03 (m, J = 30.0 Hz, 3 H); 13C NMR
(CD3CN, 400 MHz): δ = 184.0, 154.5, 154.3, 153.0, 149.5, 149.1, 141.8, 141.6, 136.5,
134.5, 129.1, 128.8, 128.1, 128.0, 125.9, 123.6, 122.5, 119.1 ppm. +ESI-MS m/z (100%)
calc. 532.99; found: 532.99. Elemental analysis calc. for C25H16BClF4N2O3Pd: C 48.35%,
H 2.60%, N 4.51%; found: C 48.31%, H 2.65%, N 4.52%.
[(Pt(Bpy)(3-Hydroxy-4’-methoxyfla)][BF4] ] Complex 5. Yield: 70% (green crystals)
UV-Vis λmax (CH3CN/nm)(ε/M-1 cm-1) (459 (33 000); 1H NMR (CD3CN, 400 MHz): δ 8.35
(d, J = 4.5 Hz, 1H), 8.21 (d, J = 4.5 Hz, 1H), 8.06 (t, J = 16.6, 4H), 7.99 (d, J = 8.2 Hz, 2H),
7.69 (d, J = 8.5 Hz, 1 H), 7.62 (t, J = 15.4 Hz, 1H), 7.48 (t, J = 12.6 Hz, 1 H), 7.36 (d, J =
8.2 Hz, 2 H), 7.25 (t, J = 14.9 Hz, 1 H), 6.79 (d, J = 8.5 Hz, 2 H), 3.82 (s, 3H) ppm. +ESI-
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HRMS m/z (relative intensity) calc. 618.30; found: 618.10. Elemental analysis calc. for
C26H19BF4N2O4Pt: C 44.28%, H 2.72%, N 3.97%; found: C 44.21%, H 2.75%, N 3.99%.
[(Pt(Bpy)(3-Hydroxy-4’-methylfla)][BF4] ] Complex 6. Yield: 87% (green crystals) UVVis λmax (CH3CN/nm)(ε/M-1 cm-1) (453 (25 000); 1H NMR (CD3CN, 400 MHz): δ 8.46 (d,
J = 4.8 Hz, 1H), 8.28 (d?, J = 4.7 Hz, 1H), 8.16 (t, J = 5.1, 4H), 7.99 (d, J = 7.6 Hz, 2H),
7.82 (d, J = 8.1 Hz, 1 H), 7.71 (t, J = 15.7 Hz, 1 H), 7.54 (m, J = 17.2 Hz, 1 H), 7.46 (d, J
= 8.6 Hz, 1 H); 7.42 (t, J = 11.3 Hz, 1H), 7.34 (t, J = 14.5, 1H), 7.10 (d, J = 7.6 Hz, 2H),
3.30 (s, 3H) ppm. +ESI-HRMS m/z (relative intensity) calc. 602.31; found: 602.10.
Elemental analysis calc. for C26H19BF4N2O3Pt: C 45.30%, H 2.78%, N 4.06%; found: C
45.33%, H 2.76%, N 4.05%.
[(Pt(Bpy)(3-Hydroxyfla)][BF4] ] Complex 7. Yield: 82% (green crystals) UV-Vis λmax
(CH3CN/nm)(ε/M-1 cm-1) (449 (11 000); 1H NMR (CD3CN, 400 MHz): δ 8.81 (d, J = 5.4
Hz, 1H), 8.53 (d, J = 5.4 Hz, 1H), 8.34 (t, J = 6.8, 4H), 8.25 (m, J = 7.2 Hz, 2H), 8.11 (d, J
= 4.1 Hz, 1 H), 7.84 (t, J = 7.8 Hz, 1 H), 7.73 (d, J = 4.5 Hz, 1 H), 7.67 (t, J = 6.5 Hz, 1 H),
7.54 (m, J = 8.5 Hz, 5H);

C{1H} NMR (CD3CN, 400 MHz): δ = 184.5, 156.5, 156.4,
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155.9, 155.2, 153.7, 152.5, 149.9, 141.8, 141.3, 135.1, 132.3, 130.3, 129.5, 129.0, 128.8,
127.1, 127.0, 124.8, 123.3, 118.9, 40.9 ppm. +ESI-HRMS m/z (relative intensity) calc.
588.29; found: 588.10. Elemental analysis calc. for C25H17BF4N2O3Pt: C 44.47%, H
2.54%, N 4.15%; found: C 44.48%, H 2.50%, N 4.14%.
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2.3 Reaction of 3 and O2
A stock solution (35 μL, 1.00 mM) of 3 in DMSO in an argon atmosphere was added
to an inorganic phosphate (IP) buffer (2 mL, pH 7.1) in a screw-capped UV cuvette.
Dioxygen was bubbled into it for 4 minutes. Carbon monoxide release was monitored by
following the decrease of complex 3’s absorbance at 434 nm for 1 h. The experiment was
repeated using complexes 1, 2 and 4 (100 μL, 1.00 mM) at their corresponding λmax. The
experiment was also repeated at higher temperature (80 °C).
2.4 Reaction with O2 under light
A stock solution (1.00 mM in DMSO) of 3 in an argon atmosphere was added to oxygensaturated acetonitrile (2 mL) in a screw-capped UV cuvette. The cuvette was irradiated
with broadband light and then monitored by UV-Vis spectroscopy in 10 s intervals three
times, then 30 s intervals three times, then 1 min. intervals three times, then 3 minutes
intervals for a total of 30 min.
A stock solution (25 μM in DMSO) of 5 in an argon atmosphere was added to oxygensaturated acetonitrile in a screw-capped UV cuvette. The cuvette was irradiated with
broadband light then monitored by UV-Vis spectroscopy in 10 min. intervals for a total of
80 min. The experiment was repeated with complexes 6 and 7.
2.5 Reaction of 1-4 and HNO
Because HNO is an analogue of dioxygen, the experiment was repeated using HNO. A
buffered stock solution of the HNO-precursor Angeli’s salt (AS) (10 mM, pH 12) was
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prepared in an argon atmosphere according to literature procedures.41 AS (200 μL, 10.00
mM) was added to an anaerobic flavonolato palladium stock solution (35 μL, 1.00 mM) in
IP buffer (2 mL, pH 7.1) in a screw-capped UV cuvette. The reaction was initiated by
gently shaking the cuvette; carbon monoxide release was monitored by following the
decrease of the substrate absorbance at 434 nm for 1 h. The experiment was repeated using
complexes 1, 2 and 4 (1.00 mM). Because NaOH is present in the IP buffer, a control
reaction was run for NaOH (100 μL, 0.1 M) reacting with complex 3 (35 μL, 1.00 mM) in
an argon atmosphere. Because sodium nitrite (NO2-) anions are a product of the
decomposition of Angeli’s salt, a control reaction was run for NO2- (100 μL, 0.1 M)
reacting with 3 (35 μL, 1.00 mM). Both control reactions were monitored by absorption
spectroscopy.
2.6 Detection of photo-induced CO release
Following literature procedures,16 argon was bubbled through complex 3 (4 μmol)
dissolved in DMSO (0.7 mL) and IP buffer (15 mL, pH 7.1) in a sealed round-bottom flask
protected from light. Angeli’s salt (10 mg ) in an argon atmosphere was added and allowed
to react. After 2h a sample of atmosphere from the head space was injected into a screwcapped UV cuvette containing an argon atmosphere with freshly prepared deoxymyoglobin
(lyophilized horse skeletal muscle) (2 mL, 15 μM) prepared by dissolving the protein in IP
buffer (2 mL, 0.01M, pH 7.1) and reduced with sodium dithionite (90:1 molar ratio with
myoglobin). The reaction was monitored spectroscopically.
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CHAPTER 3 - RESULTS AND DISCUSSION
3.1 Synthesis and characterization of Pd(II) and Pt(II) flavonolate complexes
The synthesis of metal(II) bipyridine flavonolate complexes [MIIBpyFlaR][BF4](M = Pd
(1-4), R= p-OMe (1), p-Me (2), p-H (3), p-Cl(4)); (M = Pt (5-7), (R= p-OMe (5), p-Me (6),
p-H (7)) follows a methodology that has not been previously published. The complexes
were prepared by mixing 1 equivalent of MIIBpyCl2 with 2 equivalents of AgBF4 first to
generate activated [MIIBpy(sol)2] moiety, followed by addition of 1.2 equivalents of
deprotonated flavonol. The reaction was stirred under room temperature for 2 h (1-4) or 6
h (5-7). The resulting complexes were isolated as yellow-orange (1-4) or green (5-7) BF4salts. The solid complexes 1-7 are stable in the air at room temperature for several months.
The complexes have all been characterized by 1H-NMR, 13C-NMR, UV-Vis, infrared and
fluorescence spectroscopies, and mass spectrometry, as well as elemental analysis.
3.2 Spectroscopic properties of the complexes
PdII- and PtII bipyridine flavonolate complexes (1-7) have very similar IR and electronic
spectra as seen in Table 1.
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Table 1. Summary of Infrared (IR) and Ultraviolet-Visible (UV-Vis) Data for Pd(II) and
Pt(II) bipyridine flavonolate complexes.
Complex

λmax
(nm)

Absorbance
(AU)

Extinction
Coefficient ϵ
(cm-1M-1)

νCO (cm-1)

σa

1

444

1.26

2.52x104

1530

-0.27

2

439

1.11

2.22x104

1528

-0.17

3

434

1.05

2.10x104

1524

0

4

428

1.02

2.04x104

1520

0.23

5

459

0.815

3.3 x 104

1440

-0.27

6

453

0.628

2.5 x 104

1437

-0.17

7

449

0.527

1.1 x 104

1498

0

a

Hammett constants σ for substituents (OCH3, CH3, H and Cl)42

Coordination of the flavonol to the metal site is indicated by the characteristic νco band
between 1450 and 1530 cm-1 (Figures 5-7). Compared to that of the νco vibration at 1602
cm-1 of the free flavonol, the band of complexes 1-4 is shifted by 70-80 cm-1 to lower
energies and that of complexes 5-7 by 102-152 cm-1, which can be explained by the
formation of a stable five-membered chelate rings.18,43–51
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Figure 5. FTIR spectrum of complex 5.
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Figure 6. FTIR spectrum of complex 6.
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Figure 7. FTIR spectrum of complex 7.

Neutral flavonol compounds exhibit an absorption feature in the range of 320-360 nm,
which is assigned to the π-π* transition (Figures 8-14). When dissolved in CH3CN under
anaerobic conditions, each complex 1-4 exhibits an intense absorption feature in the range
of 400–450 nm (complex 1: 444 nm (ε = 2.5 × 104 M-1cm-1 ), complex 2: 439 nm (ε = 2.2
× 104 M-1cm-1), complex 3: 434 nm (ε = 2.1 × 104 M-1cm-1), complex 4: 428 nm (ε = 2.0 ×
104 M-1cm-1). Likewise, each complex 5-7 (Figures 8-10) exhibits an electronic absorption
maxima between 449 – 459 nm when dissolved in DMSO (complex 5: 459 nm (ε = 3.3 ×
104 M-1cm-1), complex 6: 453 nm (ε = 2.5 × 104 M-1cm-1), complex 7: 449nm (ε = 1.1 × 104
M-1cm-1)).
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Figure 8. UV-Vis spectrum of complex 1 (50 μM in acetonitrile)
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Figure 9. UV-Vis spectrum of complex 2 (50 μM in acetonitrile).
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Figure 10. UV-Vis spectrum of complex 3 (50 μM in acetonitrile)
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Figure 11. UV-Vis spectrum of complex 4 (50 μM in acetonitrile).
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Figure 12. UV-Vis spectrum of complex 5 (25 μM in DMSO).

Figure 13. UV-Vis spectrum of complex 6 (25 μM in DMSO).
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Figure 14. UV-Vis spectrum of complex 7 (25 μM in DMSO).

The λmax of Pd(II) bipyridine flavonolate complexes [PdIIBpyFlaR]BF4 are red-shifted by
6–18 nm as compared to similar [CuIIBpyFla]ClO4, which was found to exhibit a square
pyramidal geometry.52 This red-shift in the absorption band relative to neutral flavonol
compounds can be explained by increased conjugation in the metal-ligand complex.17 The
bands are blue-shifted about 30 nm relative to those of free flavonolate (458 nm for
Me4Nfla18 and 465 nm for Kfla53,54). Furthermore, the λmax values of the complexes are in
order of [PtIIBpyFlaOMe]+ (5) > [PtIIBpyFlaMe]+ (6) > [PtIIBpyFlaH]+ (7) > [PdIIBpyFlaOMe]+
(1) > [PdIIBpyFlaMe]+ (2) > [PdIIBpyFlaH]+ (3) > [PdIIBpyFlaCl]+ (4), and the plot of the λmax
vs. Hammett constant σ for 1-4 is linear (R = 0.98) (Figure 15). The plot of the λmax vs.
Hammett constant σ for 5-7 is also linear (R = 0.93) (Figure 16). The largest λmax was
observed in complexes 1 and 5, which have the strongest electron-donating group (OMe),
presumably due to the best planarity and conjugation in flavonolate molecule, as confirmed
by its smallest torsion angle in [CoIILRFla] complexes.31 These results indicate that the λmax
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of the coordinated flavonolate is also affected by the electronic nature of the substituent
group in the ligands.

Figure 15. (a) UV-Vis spectrum of complex 3 (50 μM in acetonitrile, solid line) and
product after reacting with O2 in acetonitrile at 80°C (dashed line). (b) Plot of λmax of the
complexes vs. Hammett constant σ for complexes 1-4.
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Figure 16. Plot of λmax of the complexes vs. Hammett constant σ for complexes 5-7.

Fluorescence spectroscopy of complexes 5-7 are shown in Figures 17-19. The maximum
excitation wavelength is 349.2 nm (5), 341.3 nm (6), and 340.8 nm (7). The maximum
emission wavelength is 533.0 nm (5), 530.1 nm (6), and 527.4 nm (7). The Stokes shift is
183.8 nm (5), 188.8 nm (6), and 186.6 nm (7).
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Figure 17. Fluorescence spectrum of complex 5.
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Figure 18. Fluorescence spectrum of complex 6.
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Figure 19. Fluorescence spectrum of complex 7.

3.3 ESI-MS Spectrometry
The solution structures of the metal bipyridine flavonolate complexes were also
examined by ESI-MS. Each complex shows one peak cluster that can be assigned to
[PdIIBpyFlaR]+ (m/z (pos.) = 529.04 for 1, 513.04 for 2, 499.03 for 3, and 532.99 for 4) and
to [PtIIBpyFlaR]+ (m/z (pos.) = 618.10 for 5, 602.10 for 6, and 588.09 for 7). The m/z value
and isotope distribution pattern of each peak cluster match well with the calculated value
(Figures 20-26), indicating that each complex keeps its oxidation state and mononuclear
structure in solution.
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Figure 20. (a) Zoomed blank mass spectrum before sample. (b) Zoomed isotope pattern
on mass spectrum of complex 1. (c) Zoomed theoretical isotope distribution of complex
1.
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.
Figure 21. (a) Zoomed blank mass spectrum before sample. (b) Zoomed isotope pattern
on mass spectrum of complex 2. (c) Zoomed theoretical isotope distribution of complex
2.
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Figure 22. (a) Zoomed blank mass spectrum before sample. (b) Zoomed isotope pattern
on mass spectrum of complex 3. (c) Zoomed theoretical isotope distribution of complex
3.
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Figure 23. (a) Zoomed blank mass spectrum before sample. (b) Zoomed isotope pattern
on mass spectrum of complex 4. (c) Zoomed theoretical isotope distribution of complex
4.
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Figure 24. (a) Zoomed blank mass spectrum before sample. (b) Zoomed isotope pattern
on mass spectrum of complex 5. (c) Zoomed theoretical isotope distribution of complex
5.
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Figure 25. (a) Zoomed blank mass spectrum before sample. (b) Zoomed isotope pattern
on mass spectrum of complex 6. (c) Zoomed theoretical isotope distribution of complex
6.
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Figure 26. (a) Zoomed blank mass spectrum before sample. (b) Zoomed isotope pattern
on mass spectrum of complex 7. (c) Zoomed theoretical isotope distribution of complex
7.

3.4 NMR spectroscopy
More conclusive structural information was obtained from NMR analysis of the
complexes (Figures 27-38). 1H-NMR and
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C-NMR spectra of complex 3 are shown in

Figure 27 and Figure 28, respectively. In the 1H-NMR spectrum, 17 protons are seen in
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complex 3. Assignment of each proton peak was confirmed by 1H-1H COSY and 1H-13C
HSQC (Figures 29-30). Complex 7 has a very similar 1H-NMR spectrum, shown in Figure
37. The 1H-NMR spectra of complexes 1,2,4-6 (Figures 32-36) are similar but with a signal
upfield for the more shielded protons on the methyl and methoxy substituents of the
flavonolate.
In the 13C-NMR spectrum of complex 3 (Figure 28), there are 8 quaternary C atoms: 2
(C20 and C21) from bipyridyl and 6 (C1, C2, C7, C8, C9, and C10) from the flavonolate.
In addition, there are 17 tertiary C atoms, all of which were assigned by 1H-13C HSQC.
The assignment of all C atoms and H atoms were doubly confirmed by C-H long-range
couplings obtained from the 1H-13C HMBC spectrum (Figure 31). The analogous 13C-NMR
spectrum of complex 7 (Figure 38) is very similar.

Figure 27. 1H NMR spectrum of complex 3.
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Figure 28. 13C NMR spectrum of complex 3.

Figure 29. 2D 1H-1H COSY of complex 3.
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Figure 30. 2D 13C-1H HSQC of complex 3.

Figure 31. 2D 13C-1H HMBC of complex 3.

41

Figure 32. 1H NMR spectrum of complex 1.

Figure 33. 1H NMR spectrum of complex 2.
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Figure 34. 1H NMR spectrum of complex 4.

Figure 35. 1H NMR spectrum of complex 5 in CD3CN.

43

Figure 36. 1H NMR spectrum of complex 6 in CD3CN.

Figure 37. 1H NMR spectrum of complex 7 in CD3CN.

44

Figure 38. 13C NMR spectrum of complex 7 in (CD3)2SO.

3.5 Oxygenation of Pd(II) bipyridine flavonolate complexes with O2
The oxygenation reaction of Pd(II) bipyridine flavonolate complexes was followed by
monitoring the decrease of the absorbance of the coordinated flavonolate (π – π*) at the
corresponding λmax. At room temperature, no oxygenation reaction between Pd(II)
bipyridine flavonolate complexes and dioxygen occurred, as seen in Figures 39-42.
However, if the reaction is carried out at elevated temperature (80 oC), the decay of
coordinated flavonolate band was observed (Figure 15a). The similar reactivity was
observed in the reaction of [CuIIBpyFla]ClO4 with dioxygen in acetonitrile, indicating a big
energy barrier to overcome for metal bipyridine flavonolate complexes and ground state
dioxygen (3O2)52. A UV-Vis lamp with broad band light (300 nm–900 nm) was used to
examine the effect of light on the reaction between [Pd IIBpyFla]BF4 and dioxygen.
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However, unlike the reaction of [RuII(Bpy)2Fla]PF6 with dioxygen in which light speeds
up the reaction rate33, the oxygenation reaction of [PdIIBpyFlaR]BF4 was still very slow
under light. There is no difference between oxygenation reaction of Pd(II) bipyridine
flavonolate complexes with or without light, implying that light has no effect on reaction
of [PdBpyFla]BF4 with dioxygen.

Figure 39. UV-Vis absorption spectra of reaction between complex 1 and O2 with light
irradiation under Ar in acetonitrile.
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Figure 40. UV-Vis absorption spectra of reaction between complex 2 and O2 with light
irradiation under Ar in acetonitrile.

Figure 41. UV-Vis absorption spectra of reaction between complex 3 and O2 with light
irradiation under Ar in acetonitrile.
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Figure 42. UV-Vis absorption spectra of reaction between complex 4 and O2 with light
irradiation under Ar in acetonitrile.

3.6 Oxygenation of Pt(II) bipyridine flavonolate complexes with O2
The oxygenation reaction of Pt(II) bipyridine flavonolate complexes was investigated.
Changes in the electronic absorbance at λmax as a function of irradiation time were
monitored. There was no oxygenation reaction without irradiation. A decrease in the
intensity of the MLCT peak (e.g. 459 nm for complex 5) as the complexes were exposed
to broadband (300 nm–900 nm) excitation using the Rayonet photoreactor at room
temperature indicates all three complexes reacted with dioxygen (Figures 43-45).
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Figure 43. UV-Vis absorption spectra of reaction between complex 5 (25 μM) in DMSO
and O2 with light irradiation at ambient temperature.
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Figure 44. UV-Vis absorption spectra of reaction between complex 6 (25 μM) in DMSO
and O2 with light irradiation at ambient temperature.
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Figure 45. UV-Vis absorption spectra of reaction between complex 7 (25 μM) in DMSO
and O2 with light irradiation at ambient temperature.

The solutions turned from yellow-green to colorless, indicating light catalyzes the
[PtII(Bpy)Fla]BF4 oxygenation reaction. This is similar to a previously reported photoinduced reaction of [(L)Zn(3-Hfl)ClO4 (L is a bidentate nitrogen donor ligand) reacting
with oxygen.55 Since the platinum complexes underwent oxygenation reaction with
irradiation at room temperature but the palladium complexes did not, the platinum
complexes absorb the required activation energy, but the palladium complexes do not. This
is reasonable because energy is inversely related to wavelength. The platinum complexes
have a higher λmax than the palladium complexes, so the platinum complexes must be at a
lower energy in their excited state compared to palladium in its excited state.
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The energy barrier was also lower in complexes with electron-donating groups in the
para position of the flavonolato moiety, reflected in the larger λmax value of the
methoxyflavonolate complexes 1 and 5. These results indicate that the increased electron
density on the flavonolato ligand by para electron-donating substituents raises the energy
of the metal’s HOMO and shifts the π-π* absorption to lower energies, effectively lowering
the energy barrier for electron transfer to O2.55,56 The proposed mechanism of CO release
involves platinum serving as a conduit for a single electron transfer from the flavonolate
ligand to the dioxygen ligand, creating two radicals. The superoxide radical would attack
the flavonolate radical to form a bridging peroxo species, similar to the mechanism of CuII
fungal quercetin dioxygenases.55 Following oxidative cleavage of this bridge, CO would
be extruded and a depside formed.
3.7 Nitroxygenation of Pd(II) bipyridine flavonolate complexes with HNO
The simple molecule nitrosyl hydride (HNO) is the singly reduced and protonated form
of nitric oxide, NO. HNO has been reported to have similar reactivity with dioxygen
because it can be trapped by various O2-binding globins and interact with O2-dependent
oxygenases.41,57 Previous publication shows that HNO can substitute dioxygen in the
reaction with free flavonol. Nitroxygenation reaction of free flavonol (quercetin) with
HNO is much faster than that with dioxygen.58 The reaction of Pd(II) bipyridine flavonolate
complexes with HNO was investigated to provide insights on reactivity of HNO.
Following the typical procedure in a nitroxygenation assay, solutions of complex 3 and
Angeli’s salt were mixed in deaerated pH 7 phosphate buffer. The decrease in
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concentration of complex 3 was followed by the decrease in its absorbance at 434 nm.
Figures 46-49 shows the reaction spectra of [PdIIBpyFlaR]BF4 with Angeli’s salt (AS),
HNO donor, in 50mM phosphate buffer. As opposed to oxygenation reaction of Pd(II)
bipyridine flavonolate complexes with dioxygen at high temperature (80

o

C),

nitroxygenation reaction of [PdIIBpyFla]BF4 occurred at room temperature with a fast rate.
Initial kinetic analysis was performed and analyzed using the sequential reactions depicted
in equations 1-3. Rate analysis of nitroxygenation reactivity is complicated by the slow
decomposition rate of the HNO-donor Angeli’s salt and the competitive dimerization of
free HNO. The slow release of HNO from Angeli’s salt would be predicted as the ratelimiting step, but at relatively low substrate concentrations, the initial rate of reaction is
dependent on both [PdIIBpyFla]+ and [AS].

To ascertain that the CO release was due to the complex rather than another substance in
solution, a control reaction was performed with the nitrite ion (Figure 50). There was little
decrease in absorbance at λmax; nitrite ions did not cause the release of CO.
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Figure 46. UV-Vis absorption spectra of reaction between complex 1 with HNO donor
Angeli’s salt in pH 7.1 phosphate buffer.

Figure 47. UV-Vis absorption spectra of reaction between complex 2 with HNO donor
Angeli’s salt in pH 7.1 phosphate buffer.
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Figure 47. UV-Vis absorption spectra of reaction between complex 3 with HNO donor
Angeli’s salt in pH 7.1 phosphate buffer.

Figure 48. UV-Vis absorption spectra of reaction between complex 4 with HNO donor
Angeli’s salt in pH 7.1 phosphate buffer.
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Figure 49. UV-Vis absorption spectra of reaction between complex 3 and NaNO2 under
Ar in acetonitrile.

3.8 CO detection from nitroxygenation reaction of [PdBpyFla]BF4 with HNO
The product CO generated during the reaction of [PdBpyFla]BF4 with HNO was
confirmed by the conversion of a solution of deoxymyoglobin to its ferrous CO adduct
upon exposure to the head gas above the assay mixture. Figure 51 displays the UV-Vis
spectra of deoxymyoglobin and CO-myoglobin. The progress of the reaction was
monitored by the shift in Soret absorbance from 434 to 423 nm, confirming formation of
CO-FeIIMb.
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Figure 50. UV-Vis spectra of formation of CO-FeIIMb (dashed line) by deoxymyoglobin trapping of CO released in the reaction of complex 3 with Angeli’s salt.

Regarding the mechanism of nitroxygenation of metal flavonolate complex with HNO,
it was reported that the metal ion acts as a conduit for an internal electron transfer between
the metal-bound flavonol and HNO, also orienting the resultant organic radicals to facilitate
coupling.57 Scheme 2 depicts possible reaction pathways for nitroxygenation activity of
Pd(II) bipyridine flavonolate complexes. The reaction is proposed to go through an initial
single electron transfer to form PdIII – aminoxyl radical adduct, A. Then, a second single
electron transfer from substrate to metal generates the substrate radical, B. Radical coupling
would form an alkylhydroxamate intermediate, C, and then nucleophilic attack would
generate an isoxazolidine bridge, D, which then decomposes to parent carboximidic ester,
E, and CO. The oxygenation reaction with the Pt(II) bipyridine flavonolate complexes is
likely to be similar, as depicted in Scheme 3.

56

Scheme 2. Proposed mechanism to release CO upon nitroxygenation.

Scheme 3. Proposed mechanism to release CO upon oxygenation.
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CHAPTER 4 - CONCLUSIONS
In summary, we designed and synthesized a series of Pd II flavonolate complexes
[PdIIBpyFlaR] (R= p-OMe (1), p-Me (2), p-H (3) and p-Cl (4) and PtII flavonolate
complexes [PtIIBpyFlaR] (R = p-OMe (5), p-Me (6), and p-H (7)) as CO-releasing agents.
Their structures, spectroscopic features and reaction towards dioxygen and HNO were
investigated. The reaction of palladium(II) bipyridine flavonolate complexes with O2 at
room temperature with and without light irradiation doesn’t occur, while their reaction with
HNO at room temperature happens at a fast rate. The product CO generated from the
nitroxygenation reaction of [PdIIBpyFlaR] with HNO was detected by deoxymyoglobin
with the shift in Soret absorbance from 434 to 423 nm. The platinum(II) bipyridine
flavonolate complexes are stable in the dark but reacted with O2 at room temperature with
light irradiation to produce putative CO and an O-benzoylsalicylate product. The
mechanism of nitroxygenation reaction was proposed to proceed through initial electron
transfer between metal PdII and HNO. The mechanism of the platinum complexes’
oxygenation reaction is probably similar with an electron transfer between PtII and O2. The
complexes’ photoreactivity offers temporospatial control of CO release with potential
anticancer applications. Because CO can be released at room temperature rather than
requiring temperatures above body temperature, these complexes could be suitable for
treatments in the human body. Since the CO release occurs only with photo-irradiation, the
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CO release can be controlled, for example, to deliver small amounts of carbon monoxide
selectively to cancer cells. Finally, the fact that visible light is the trigger for the CO release
means the treatment would not expose a human to harmful UV light. Future work could
include quantifying the CO release and testing the complexes for oxygenation reactivity in
aqueous environments to mimic biologically relevant conditions. Additionally, the toxicity
of the byproducts should be investigated to establish the therapeutic potential of these
complexes.
.
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